Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
stocks
Stellar growth from ASX retailer but markets still too optimistic
stocks
How to focus on the right things this reporting season
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,150.30 | 32.70 | 0.36% |
CAC 40 | 7,753.42 | 54.90 | 0.71% |
DAX 40 | 24,024.78 | 56.56 | -0.23% |
Dow JONES (US) | 44,455.38 | 480.29 | 1.09% |
FTSE 100 | 9,147.81 | 18.10 | 0.20% |
HKSE | 24,969.68 | 62.87 | 0.25% |
NASDAQ | 21,652.36 | 266.96 | 1.25% |
Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
NZX 50 Index | 12,759.68 | 152.18 | -1.18% |
S&P 500 | 6,438.78 | 65.33 | 1.03% |
S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
SSE Composite Index | 3,665.92 | 18.37 | 0.50% |